retatrutide

Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide, showing average weight losses of up to 28.7% in its first phase 3 readout. Top-line results from the TRIUMPH-4 trial, carried out in patients overweight or with obesity and knee osteoarthritis, raise expectations for…